Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
about
AcromegalyClinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluationAcromegaly pathogenesis and treatmentPasireotide: a novel treatment for patients with acromegalyThe risks of overlooking the diagnosis of secreting pituitary adenomasManagement of acromegaly in Latin America: expert panel recommendationsThe endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.A structural and functional acromegaly classificationSurgical management of acromegaly in a resource-challenged environment.Clinical, quality of life, and economic value of acromegaly disease controlAcromegaly with cardiomyopathy, cardiac thrombus and hemorrhagic cerebral infarct: a case report of therapeutic dilemma with review of literature.The role of growth hormone-receptor antagonism in relation to acromegaly.Current pharmacotherapy for acromegaly: a review.Growth hormone and its disordersEtiologic aspects and management of acromegaly.Resistance to somatostatin analogs in acromegaly: an evolving concept?Newer options in the management of acromegaly.Changing paradigms in the surgical and medical management of acromegaly.Is there still a role for radiotherapy in acromegaly?Osteosarcoma and acromegaly: a case report and review of the literature.Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?Growth Hormone and Treatment Controversy; Long Term Safety of rGH.Cost of management of invasive growth hormone-secreting macroadenoma.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Excess mortality in acromegaly.A consensus on the diagnosis and treatment of acromegaly complications.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Medical therapy in acromegaly.Excess mortality for patients with residual disease following resection of pituitary adenomas.Acromegaly: presentation, morbidity and treatment outcomes at a single centre.What is active acromegaly and which parameters do we have?Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsThe place of medical treatment of acromegaly: current status and perspectives.Octreotide for acromegaly treatment: a reappraisal.Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.Update on prognostic factors in acromegaly: Is a risk score possible?A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry.New therapeutic agents for acromegaly.Current and future medical treatments for patients with acromegaly.
P2860
Q21202912-C79C5125-5FB8-4E19-92FE-3D51344DE602Q21254711-72964D3C-1802-4FE3-9E23-82F6CCC052A5Q24647360-6E4391FB-8F5F-47AF-A7AD-30C614D12A92Q26774437-4CF9DE45-4492-423F-99F7-7564E71D5959Q28076665-7055974C-85FC-4387-BD58-62CEC3BC38FEQ33794388-59A45679-415B-4FA0-9C99-BACBA488546FQ34031906-066CCB32-4669-4D9B-ADE2-BC545EB3314BQ34810811-449CFBAA-DB11-4D4D-A850-793971C7AC35Q35041686-47C92040-0E66-4D1A-B8E5-110B5C9A9708Q35137675-8D28B631-7034-47A4-9C1C-388BDA1002AFQ35428187-1C39DEDA-1D03-466D-8C31-837C49681115Q35925517-CCB931B8-7162-4D9E-AA2D-F6A9C293B53DQ36301564-B00BD86F-C60B-4A15-8ED8-FBC7A09F2284Q36362200-7FBE14F6-1C2D-4B9C-ADAD-A62E9D574D59Q36380875-C175420D-88BB-4445-841A-60980D964345Q36428225-34FBE76C-2F3B-487A-8507-1CBAFE56AF66Q36509265-D6C63D05-81B0-4402-A977-880A9CD7B220Q36605363-5050DD3F-C4AE-490B-9609-D4FA5BA50A05Q36626513-F3DF3D76-451C-4123-8693-B0D197DEB85BQ36720803-1A2C0B61-2C7A-4531-8922-406AE5D8BE67Q36845980-CD647256-79C8-440B-9B23-EC10B9575C30Q36918629-408A137B-6DE1-4391-A5EC-031EFB1EEE32Q36937812-7E4BDED4-FE4F-4843-A5CB-999CB72004E8Q37029532-BF865EEC-74A7-425F-95BF-4EBC29703826Q37050111-B04BB2F2-5769-4866-B2B9-787E640E7662Q37061155-D4FE37DD-307B-497B-9DBE-430EFD887C0EQ37321948-1E6F513F-6BBE-4718-AB76-6D27433D3566Q37859250-FE0F06DC-793B-4AE1-8313-DA3CD42CA28CQ37863050-CC586A53-5591-4011-9994-91D18539ECCAQ37890467-08ADE505-D3E6-4085-829E-794446AA2519Q37977989-F299CE92-2C14-440B-9B89-6F743DA9A2EAQ37980741-E8B69490-7278-44A0-BDC8-241B66DD6855Q38100275-3F1344CF-762F-416D-9868-2F6FB49EF4ABQ38152458-C7A976B0-5071-4069-81B8-6B03056DB218Q38185306-EE1E0965-B7D3-41C8-9E03-777D1D08099EQ38214473-0E8D4EE8-181A-4F91-A954-84F2C9F26618Q38373377-271C74B9-1E53-41BA-A583-0F92FE010E80Q38624632-B78E85AB-6EEC-4292-9AB5-2E49A8A0015BQ38648739-082DC98D-5124-4801-AF40-BB0BC2B30FA7Q38847622-3BEB804B-3911-48E1-8FBB-1DB3A838E145
P2860
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Growth hormone and pituitary r ...... y in patients with acromegaly.
@en
Growth hormone and pituitary r ...... y in patients with acromegaly.
@nl
type
label
Growth hormone and pituitary r ...... y in patients with acromegaly.
@en
Growth hormone and pituitary r ...... y in patients with acromegaly.
@nl
prefLabel
Growth hormone and pituitary r ...... y in patients with acromegaly.
@en
Growth hormone and pituitary r ...... y in patients with acromegaly.
@nl
P2093
P921
P356
P1476
Growth hormone and pituitary r ...... y in patients with acromegaly.
@en
P2093
P304
P356
10.1210/JC.2003-031584
P407
P577
2004-04-01T00:00:00Z